Open access
Aug 2026
Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
It is suggested that zanubrutinib offers improved PFS over FCR in fit, treatment-naive patients with CLL, further supporting zanubrutinib as a first-line CLL treatment for multiple patient profiles.
T. Munir, L. Barnieh, L. Mohseninejad et al.
· Journal of Comparative Effec... · 0 citations